###begin article-title 0
###xml 15 20 <span type="species:ncbi:9606">Human</span>
Association of Human Herpesvirus-6B with Mesial Temporal Lobe Epilepsy
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 21 26 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 146 151 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 227 232 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 421 429 <span type="species:ncbi:9606">patients</span>
###xml 634 639 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 700 708 <span type="species:ncbi:9606">patients</span>
Human herpesvirus-6 (HHV-6) is a beta-herpesvirus with 90% seroprevalence that infects and establishes latency in the central nervous system. Two HHV-6 variants are known: HHV-6A and HHV-6B. Active infection or reactivation of HHV-6 in the brain is associated with neurological disorders, including epilepsy, encephalitis, and multiple sclerosis. In a preliminary study, we found HHV-6B DNA in resected brain tissue from patients with mesial temporal lobe epilepsy (MTLE) and have localized viral antigen to glial fibrillary acidic protein (GFAP)-positive glia in the same brain sections. We sought, first, to determine the extent of HHV-6 infection in brain material resected from MTLE and non-MTLE patients; and second, to establish in vitro primary astrocyte cultures from freshly resected brain material and determine expression of glutamate transporters.
###end p 2
###begin title 3
Methods and Findings
###end title 3
###begin p 4
###xml 118 126 <span type="species:ncbi:9606">patients</span>
###xml 256 264 <span type="species:ncbi:9606">patients</span>
###xml 314 322 <span type="species:ncbi:9606">patients</span>
###xml 593 598 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 707 712 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 764 769 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 811 816 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 970 975 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
HHV-6B infection in astrocytes and brain specimens was investigated in resected brain material from MTLE and non-MTLE patients using PCR and immunofluorescence. HHV-6B viral DNA was detected by TaqMan PCR in brain resections from 11 of 16 (69%) additional patients with MTLE and from zero of seven (0%) additional patients without MTLE. All brain regions that tested positive by HHV-6B variant-specific TaqMan PCR were positive for viral DNA by nested PCR. Primary astrocytes were isolated and cultured from seven epilepsy brain resections and astrocyte purity was defined by GFAP reactivity. HHV-6 gp116/54/64 antigen was detected in primary cultured GFAP-positive astrocytes from resected tissue that was HHV-6 DNA positive-the first demonstration of an ex vivo HHV-6-infected astrocyte culture isolated from HHV-6-positive brain material. Previous work has shown that MTLE is related to glutamate transporter dysfunction. We infected astrocyte cultures in vitro with HHV-6 and found a marked decrease in glutamate transporter EAAT-2 expression.
###end p 4
###begin title 5
Conclusions
###end title 5
###begin p 6
###xml 49 57 <span type="species:ncbi:9606">patients</span>
Overall, we have now detected HHV-6B in 15 of 24 patients with mesial temporal sclerosis/MTLE, in contrast to zero of 14 with other syndromes. Our results suggest a potential etiology and pathogenic mechanism for MTLE.
###end p 6
###begin p 7
###xml 45 50 <span type="species:ncbi:9606">human</span>
###xml 104 112 <span type="species:ncbi:9606">patients</span>
Steve Jacobson and colleagues report finding human herpesvirus-6B DNA in brain resections from 11 of 16 patients with mesial temporal lobe epilepsy, strengthening the evidence for a role for this virus in this condition.
###end p 7
###begin title 8
Editors' Summary
###end title 8
###begin title 9
Background.
###end title 9
###begin p 10
###xml 380 388 <span type="species:ncbi:9606">patients</span>
Epilepsy is a common brain disorder caused by a sudden, excessive electrical discharge in a cluster of neurons-the cells that transmit electrical messages between the body and the brain. Its symptoms depend on which part of the brain is affected by this electrical firestorm and how far the disturbance spreads. When only part of the brain is affected (a partial seizure or fit), patients may see or smell strange things, recall forgotten memories, or have part of their body jerk uncontrollably. When the electrical disturbance spreads across the whole brain (a generalized seizure), there may be loss of consciousness and/or the whole body may become rigid or jerk. Epilepsy is usually controlled with anti-epileptic drugs or, in very severe focal cases, surgery to the area of the brain where the seizure starts. Although head injuries or brain tumors can trigger epilepsy, the cause of most cases of epilepsy is unknown.
###end p 10
###begin title 11
Why Was This Study Done?
###end title 11
###begin p 12
###xml 182 202 <span type="species:ncbi:32604">human herpesvirus 6B</span>
###xml 303 311 <span type="species:ncbi:9606">Patients</span>
###xml 607 615 <span type="species:ncbi:9606">children</span>
###xml 622 628 <span type="species:ncbi:9606">people</span>
###xml 866 874 <span type="species:ncbi:9606">patients</span>
Knowing what causes epilepsy might lead to better treatments for it. One possibility is that infections trigger epilepsy. The researchers in this study asked whether infections with human herpesvirus 6B (HHV-6B) are associated with a common type of epilepsy called mesial temporal lobe epilepsy (MTLE). Patients with MTLE often have extensive scarring in the hippocampus, a brain region responsible for memory that lies deep within a bigger region called the temporal lobe. Hippocampal scarring and MTLE are associated with a history of fever-induced fits, and HHV-6B infection can cause such fits in young children. Most people become infected with HHV-6B (or the closely related HHV-6A) early in life. The virus then remains latent for years within the brain and elsewhere. Given these facts and a previous investigation that showed that brain tissue from several patients with MTLE contained HHV-6B, the researchers reasoned that it was worth investigating HHV-6B as a cause of MTLE.
###end p 12
###begin title 13
What Did the Researchers Do and Find?
###end title 13
###begin p 14
###xml 84 92 <span type="species:ncbi:9606">patients</span>
###xml 153 161 <span type="species:ncbi:9606">patients</span>
###xml 197 205 <span type="species:ncbi:9606">patients</span>
###xml 366 374 <span type="species:ncbi:9606">patients</span>
###xml 398 403 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 469 476 <span type="species:ncbi:9606">patient</span>
###xml 552 559 <span type="species:ncbi:9606">patient</span>
###xml 1284 1291 <span type="species:ncbi:9606">patient</span>
###xml 1453 1460 <span type="species:ncbi:9606">patient</span>
The researchers first looked for HHV-6B DNA in brain tissue surgically removed from patients with MTLE or another type of epilepsy. Tissue from 11 of 16 patients with MTLE (but from 0 of 7 control patients) contained HHV-6B DNA. When the researchers grew astrocytes (a type of brain cell) from some of these samples, only those from HHV-6B DNA-positive samples from patients with MTLE expressed an HHV-6-specific protein. Next, the researchers investigated in detail a patient with MTLE who had four sequential operations to control his epilepsy. This patient's hippocampus, which was removed in his first operation, contained a higher level of HHV-6B DNA than the tissues removed in later operations. After the fourth operation (which removed half of his brain and cured his epilepsy), astrocytes grown from the temporal lobe and the frontal/parietal lobe (a brain region next to the temporal lobe) but not the frontal and occipital lobes contained HHV-6B DNA and expressed a viral protein. The researchers also measured the production by these various astrocytes of a substance that moves glutamate (an amino acid that also acts as a neurotransmitter) across cell membranes-MTLE has been associated with a glutamate transporter deficiency. Consistent with this, astrocytes from the patient's temporal lobe made no glutamate transporter mRNA (mRNA is an essential precursor for protein to be produced). Finally, infection of astrocytes isolated from a patient without MTLE with HHV-6B greatly reduced expression of glutamate transporter in these astrocytes.
###end p 14
###begin title 15
What Do These Findings Mean?
###end title 15
###begin p 16
###xml 94 102 <span type="species:ncbi:9606">patients</span>
###xml 121 129 <span type="species:ncbi:9606">patients</span>
###xml 385 392 <span type="species:ncbi:9606">patient</span>
###xml 787 795 <span type="species:ncbi:9606">patients</span>
These findings, together with those from the previous study, reveal that nearly two-thirds of patients with MTLE (but no patients with other forms of epilepsy) have an active HHV-6B infection in the brain region where their epilepsy originates. Overall, they provide strong support for the idea that HHV-6B infections might cause MTLE, particularly given the results obtained from the patient whose condition only improved after multiple brain operations had removed all the virally infected material. Furthermore, the demonstration that HHV-6B infection reduces glutamate transporter expression in astrocytes suggests that HHV-6B infection might cause astrocyte dysfunction. This dysfunction could lead to injury of the sensitive neurons in the hippocampus and trigger MTLE. Additional patients now need to be studied both to confirm the association between HHV-6B infection and MTLE and to discover exactly how this virus triggers epilepsy.
###end p 16
###begin title 17
Additional Information.
###end title 17
###begin p 18
Please access these Web sites via the online version of this summary at .
###end p 18
###begin p 19
MedlinePlus encyclopedia page on  (in English and Spanish)
###end p 19
###begin p 20
World Health Organization  (in English, French, Spanish, Russian, Arabic, and Chinese)
###end p 20
###begin p 21
US National Institute for Neurological Disorders and Stroke  (in English and Spanish)
###end p 21
###begin p 22
UK National Health Service Direct  (in several languages)
###end p 22
###begin p 23
, an educational Web site prepared by Eric Chudler (University of Washington, Seattle, Washington, United States), who also has a site that includes information on  (mainly in English but some sections in other languages as well)
###end p 23
###begin p 24
###xml 35 63 35 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Emerging Infectious Diseases</italic>
A short scientific  in the journal Emerging Infectious Diseases
###end p 24
###begin title 25
Introduction
###end title 25
###begin p 26
###xml 158 159 155 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b001">1</xref>
###xml 216 217 213 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b002">2</xref>
###xml 281 282 278 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b003">3</xref>
###xml 445 446 442 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b004">4</xref>
###xml 487 488 484 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b005">5</xref>
###xml 646 647 643 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b006">6</xref>
###xml 822 823 819 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b007">7</xref>
###xml 824 825 821 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b008">8</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 21 26 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 95 103 <span type="species:ncbi:9606">patients</span>
###xml 143 146 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 162 167 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 181 187 <span type="species:ncbi:9606">humans</span>
###xml 310 315 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 491 496 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 549 557 <span type="species:ncbi:9606">children</span>
###xml 650 655 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 715 723 <span type="species:ncbi:9606">patients</span>
Human herpesvirus-6 (HHV-6) is a beta-herpesvirus first isolated in 1986 from immunosuppressed patients with lymphoproliferative disorders and HIV infection [1]. HHV-6 infects most humans between 6 and 12 mo of age [2], and more than 90% of the general population is seropositive [3]. After primary infection, HHV-6 can establish lifelong latency, with the viral genome persisting in peripheral blood mononuclear cells (PBMCs), salivary glands [4], and the central nervous system (CNS) [5]. HHV-6 DNA has been detected in the cerebrospinal fluid of children during primary infection and subsequent to infection, indicating CNS viral persistence [6]. HHV-6 reactivation may contribute to disease in immunosuppressed patients following bone marrow or solid-organ transplantation, and in those with chronic fatigue syndrome [7,8].
###end p 26
###begin p 27
###xml 232 233 232 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b009">9</xref>
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b010">10</xref>
###xml 544 546 544 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b011">11</xref>
###xml 547 549 547 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b013">13</xref>
###xml 495 500 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
Two variants of the virus have been identified, A and B, with nucleotide sequence homology between 88% and 96%. HHV-6A has been implicated in multiple sclerosis, and is associated with viral persistence and reactivation in the CNS [9,10]. HHV-6B is primarily associated with symptomatic infections during infancy and is the causative agent of exanthem subitum. Although HHV-6B is detected more frequently in PBMCs of healthy adults in the US population and may constitute the majority of latent HHV-6 infection, HHV-6A may be more neurotropic [11-13].
###end p 27
###begin p 28
###xml 50 52 50 52 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b014">14</xref>
###xml 53 55 53 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b017">17</xref>
###xml 310 312 310 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b018">18</xref>
###xml 313 315 313 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b020">20</xref>
###xml 103 108 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 118 123 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 178 185 <span type="species:ncbi:9606">infants</span>
###xml 196 204 <span type="species:ncbi:9606">children</span>
###xml 253 258 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
While associations with adult neurologic disease [14-17] are thought to involve reactivation of latent HHV-6, primary HHV-6 infection is associated with febrile seizures in both infants and young children. The incidence of febrile seizures with primary HHV-6 infection ranges from 8%-20% in the US population [18-20].
###end p 28
###begin p 29
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b021">21</xref>
###xml 592 594 592 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b022">22</xref>
###xml 595 597 595 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b023">23</xref>
###xml 805 807 805 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b024">24</xref>
###xml 808 810 808 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b025">25</xref>
###xml 228 236 <span type="species:ncbi:9606">patients</span>
Epilepsy is one of the most common and severe neurological disorders, with a prevalence of 0.6%-1%, and a large social and economic cost [21]. Despite recent diagnostic advances, the etiology of epilepsy in a high percentage of patients remains unknown, although a wide range of infections is associated with the broad category of seizure disorders. Mesial temporal lobe epilepsy (MTLE) is one of the most common and intractable forms of seizure disorder. MTLE usually begins in childhood and is often associated with a history of prolonged or complex (and possibly simple) febrile seizures [22,23]. Mesial temporal sclerosis (MTS), with extensive astrogliosis and neuronal loss, is the most common pathological finding in MTLE. Imaging studies have found an association between febrile seizures and MTS [24,25].
###end p 29
###begin p 30
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b026">26</xref>
###xml 418 420 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b015">15</xref>
###xml 509 511 509 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b027">27</xref>
###xml 535 537 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b013">13</xref>
###xml 747 749 747 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b028">28</xref>
###xml 750 752 750 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b031">31</xref>
###xml 181 189 <span type="species:ncbi:9606">patients</span>
###xml 397 402 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 423 428 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 475 483 <span type="species:ncbi:9606">patients</span>
###xml 650 655 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 667 672 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 729 734 <span type="species:ncbi:9606">human</span>
Temporal lobectomy is an effective treatment for MTLE, achieving significantly better seizure control than antiepileptic drugs [26]. In a preliminary study of brain resections from patients with MTLE, we detected HHV-6B DNA at high viral loads in hippocampal sections, with viral antigen colocalized to glial fibrillary acidic protein (GFAP)-positive cells, confirming the in vivo localization of HHV-6 to astrocytes [15]. HHV-6 is present in astrocytes in brain tissue from patients with multiple sclerosis [27], limbic encephalitis [13], and post-bone marrow transplantation encephalitis, suggesting that astrocytes may be an in vivo reservoir for HHV-6. In vitro, HHV-6 infects a wide variety of cell types, including primary human astrocytes [28-31].
###end p 30
###begin p 31
###xml 65 70 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 139 147 <span type="species:ncbi:9606">patients</span>
Here, we extend our previous investigations on the prevalence of HHV-6 infection in the hippocampus and temporal lobe from a new series of patients with MTLE and non-MTLE-related intractable epilepsy.
###end p 31
###begin title 32
Materials and Methods
###end title 32
###begin title 33
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 33
###begin p 34
###xml 28 35 28 35 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040180-t001">Table 1</xref>
###xml 905 906 901 902 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1119 1126 1115 1122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040180-t001">Table 1</xref>
###xml 1296 1298 1292 1294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b032">32</xref>
###xml 1299 1301 1295 1297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b033">33</xref>
###xml 18 26 <span type="species:ncbi:9606">patients</span>
###xml 249 257 <span type="species:ncbi:9606">Children</span>
###xml 387 394 <span type="species:ncbi:9606">patient</span>
###xml 822 830 <span type="species:ncbi:9606">patients</span>
###xml 1006 1014 <span type="species:ncbi:9606">patients</span>
###xml 1034 1042 <span type="species:ncbi:9606">patients</span>
###xml 1061 1069 <span type="species:ncbi:9606">patients</span>
###xml 1137 1145 <span type="species:ncbi:9606">patients</span>
###xml 1180 1187 <span type="species:ncbi:9606">patient</span>
###xml 1335 1342 <span type="species:ncbi:9606">patient</span>
###xml 1344 1351 <span type="species:ncbi:9606">patient</span>
We studied 22 new patients (Table 1) referred for evaluation to the Clinical Epilepsy Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health (NINDS/NIH; Bethesda, Maryland), or to the Department of Neurology Children's National Medical Center (CNMC; Washington, D. C.). Of these, 13 had surgery at NIH and nine had surgery at CNMC. Protocols for patient evaluation and surgical sample collection were approved by the NINDS and CNMC Intramural Clinical Research Committees. Clinical evaluation in each case included ictal video-EEG monitoring, 3-D-volumetric fast spin echo; and axial T1 and T2, coronal T2, and flair sequences performed on a 1.5 Tesla scanner (General Electric, ). Mean age at seizure onset was 10.8 +/- 10.7 y, and mean age at surgery was 21.4 +/- 12.4 y. The 15 patients with MTLE had a significantly older age at surgery (27.4 y versus 14.9 y; p < 0.03) and a nonsignificant trend toward lower seizure onset age (7 y versus 12 y) than the seven patients without MTLE. Five patients with MTLE, but no patients without MTLE, had a history of febrile seizures (Table 1). All the patients with MTLE, compared with only one patient without MTLE who had a ganglioglioma, had clinical, electrographic, and/or imaging characteristics of MTLE [32,33]. We also studied one additional patient (patient 16) who presented with typical temporal lobe epilepsy but then developed a diffuse epileptic syndrome, resulting in a hemispherectomy.
###end p 34
###begin p 35
###xml 4 11 <span type="species:ncbi:9606">patient</span>
###xml 44 47 <span type="species:ncbi:9606">boy</span>
###xml 1361 1368 <span type="species:ncbi:9606">patient</span>
The patient 16 was an 8-y-old, right-handed boy with a history of febrile seizures presented with sudden onset of frequent complex partial and rare secondary generalized seizures, without clear etiology. Complex partial seizures were characterized were characterized by anxiety and repetition of a short verbal phrase, followed by staring and aphemia with preserved comprehension. Initial EEG showed left-sided slowing; MRI showed left temporal fullness and increased T2 signal. Cerebrospinal fluid revealed no red and three white cells, a protein of 13, and glucose of 77 mg/100 ml. Despite negative PCR for herpes, acyclovir was started. Seizures persisted despite eight antiepileptic drugs, steroids, IVIG, ganciclovir, and a vagal nerve stimulator. EEG showed left temporal periodic epileptiform discharges and left frontal and right sharp waves. A left mesial temporal lobectomy led to transient improvement, but within 2 mo seizure frequency approached baseline levels with semiology unchanged. MRI was unchanged, and there were no focal neurological findings. Invasive monitoring revealed left mid/posterior superior temporal gyrus seizure onset. After resection, frequent electrographic and clinical seizures arose from inferior and middle temporal gyrus and frontal lobe. After several additional focal resections, a hemispherectomy was performed. The patient has been seizure free without anticonvulsants for 1 y. He has a right hemiparesis with little finger function, mild receptive deficits, and more severe expressive deficits; language is improving.
###end p 35
###begin p 36
###xml 4 11 <span type="species:ncbi:9606">patient</span>
###xml 288 296 <span type="species:ncbi:9606">patients</span>
###xml 562 569 <span type="species:ncbi:9606">patient</span>
All patient surgical samples were reviewed by a clinical neuropathologist before submission for virological study. Samples from mesial temporal and neocortical resections and lateral temporal lobe resections were fixed in formalin and processed for standard pathological examination. All patients with MTS/MTLE showed variable degrees of neuronal loss and gliosis preferentially affecting the CA1 and CA3 areas, but also markedly affecting CA4, CA2, and the dentate gyrus in more severe cases. There was no evidence of inflammation or neuronal inclusions in any patient with MTS/MTLE.
###end p 36
###begin title 37
Sample Collection
###end title 37
###begin p 38
For isolation of PBMCs, blood samples were drawn into acid citrate dextrose solution A tubes (Becton Dickinson, ) and were separated using lymphocyte separation medium (ICN Biomedicals, ). Cells were stored in liquid nitrogen prior to DNA extraction. Serum samples were extracted within 4 h of collection. Fresh brain material was obtained during epilepsy brain resection. Brain tissue was stored on ice in Hibernate A medium, and astrocyte isolation was initiated within 30 min after obtaining tissue.
###end p 38
###begin title 39
DNA and RNA Extraction
###end title 39
###begin p 40
###xml 454 461 <span type="species:ncbi:9606">patient</span>
DNA and RNA were isolated from fresh brain tissue using commercially available extraction kits according to manufacturers' instructions. The QIAamp blood kit was used for DNA extraction from PBMCs, the QIAamp Viral RNA kit was used for DNA extraction from serum (1.2 ml), and the DNeasy tissue kit (all kits from Qiagen, ) was used for DNA extraction from fresh brain tissue. DNA and RNA were also extracted from cultured primary astroytes obtained from patient brain resections using DNeasy and RNeasy extraction kits (Qiagen). For RNA extraction from tissue, finely minced brain samples were resuspended in 350 mul QIAzol lysis reagent (Qiagen) and stored at -70 degreesC until use. RNA extraction was performed as per the manufacturer's directions using the RNeasy lipid tissue mini kit (Qiagen).
###end p 40
###begin title 41
###xml 15 20 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
Nested PCR for HHV-6 Major Capsid Protein
###end title 41
###begin p 42
###xml 116 136 116 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">major capsid protein</italic>
###xml 142 147 142 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(MCP)</italic>
###xml 158 159 158 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b009">9</xref>
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b034">34</xref>
###xml 151 156 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
DNA amplification was performed, using nested primers specific for a highly conserved sequence corresponding to the major capsid protein gene (MCP) of HHV-6 [9,34]. The external primers amplified a 520 bp sequence, and the internal primers amplified a 258 bp sequence. PCR was performed using the Taq PCR master mix kit (Qiagen) as per manufacturer's instructions. DNA was amplified with 0.5 muM final primer concentration for 35 cycles using the following conditions: denaturation at 92 degreesC for 0.3 min, annealing at 55 degreesC for 0.3 min, and extension at 72 degreesC for 0.32 min. A total of 5 mul of primary PCR product was amplified using the internal primers with the same PCR conditions. A total of 10 mul of PCR product was subjected to electrophoresis on a 1.5% agarose gel and visualized by ethidium bromide staining.
###end p 42
###begin title 43
Real-Time Quantitative PCR
###end title 43
###begin p 44
###xml 130 132 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b015">15</xref>
###xml 133 135 133 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b035">35</xref>
###xml 463 465 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b015">15</xref>
###xml 614 615 608 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 673 674 661 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 13 20 <span type="species:ncbi:9606">patient</span>
###xml 217 222 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 852 857 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
Viral DNA in patient samples was quantified using TaqMan PCR with primers specific for HHV-6A and HHV-6B as described previously [15,35]. The A- and B-specific primers are located within the immediate early region of HHV-6 and bind specifically to their respective variants. Control experiments demonstrated that A-specific primers amplified only the HHV-6A laboratory strains U1102 and GS, and that B-specific primers amplified the HHV-6B laboratory strain Z29 [15]. Standard and sample DNA were amplified in a 96-well reaction plate using the following conditions: 50 degreesC for 2 min for activation of uracil-N-glycosylase, 95 degreesC for 10 min to inactivate uracil-N-glycosylase, and 45 cycles of 95 degreesC for 15 s (denaturation) and 60 degreesC for 1 min (annealing and extension). All standards and samples were assayed in triplicate, and HHV-6 viral load was normalized to actin.
###end p 44
###begin title 45
Primary Astrocyte Culture
###end title 45
###begin p 46
Fresh tissue was obtained from epilepsy brain resections performed at NIH or CNMC. Tissue was kept on ice in Hibernate A medium (containing 2% B27 supplement, 0.5 mM glutamine, fungicide, and 1% penicillin/streptomycin). Meninges and blood vessels were removed, and tissue was minced into small pieces and dissociated in Earl balanced salt solution (containing 0.01% DNase, 20 U/ml papain, and 1:100 penicillin/streptomycin) in a 37 degreesC shaking water bath for 1 h. Digested tissue was mechanically dissociated with sterile pipettes and passed through a 60 mum filter. The single-cell suspension was centrifuged at 1,500 rpm for 10 min and separated on a Percoll gradient for 30 min at 15,000 rpm. The glial cell layer was isolated, washed, and plated overnight in poly-L-lysine coated flasks or two-well chamber slides in astrocytic medium (DMEM/F12 containing 10% FBS, 1% penicillin/streptomycin, and 0.01% gentamicin). Primary cultures were allowed to adhere overnight, and fresh medium was added the following day. After 3-4 wk in culture, astrocytes were stained for GFAP to determine culture purity.
###end p 46
###begin title 47
Immunofluorescence
###end title 47
###begin p 48
###xml 69 76 69 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040180-t002">Table 2</xref>
###xml 116 123 116 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040180-t001">Table 1</xref>
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b015">15</xref>
###xml 38 46 <span type="species:ncbi:9606">patients</span>
###xml 103 111 <span type="species:ncbi:9606">patients</span>
###xml 129 136 <span type="species:ncbi:9606">patient</span>
###xml 165 172 <span type="species:ncbi:9606">patient</span>
###xml 306 311 <span type="species:ncbi:10090">mouse</span>
###xml 365 371 <span type="species:ncbi:9986">rabbit</span>
###xml 401 406 <span type="species:ncbi:10090">mouse</span>
###xml 682 688 <span type="species:ncbi:9986">rabbit</span>
###xml 720 725 <span type="species:ncbi:10090">mouse</span>
###xml 762 767 <span type="species:ncbi:10090">mouse</span>
Primary astrocytes were isolated from patients with MTLE included in Table 2. Astrocytes from epilepsy patients 15 (Table 1) and patient 2a (previously described as patient 2 [15]) were grown on poly-L-lysine-coated chamber slides for 3-4 wk. Primary antibodies were prepared in PBS and consisted of 1:100 mouse anti-gp116/54/64 (Advanced Biotechnologies, ), 1:100 rabbit anti-GFAP (DAKO, ), and 1:50 mouse anti-microglia marker CD68 (Santa Cruz Biotechnology, ). Slides were incubated with primary antibodies for 1 h at room temperature and then washed three times in PBS. Secondary antibodies conjugated to the appropriate fluorophore (Molecular Probes, ) consisted of 1:100 anti-rabbit IgG FITC (green), 1:1,000 anti-mouse IgG rhodamine (red), and 1:100 anti-mouse IgG AMCA (blue). Slides were incubated with secondary antibody for 1 h at room temperature and washed three times in PBS. Where indicated, slides were counterstained with DAPI in mounting media (Molecular Probes). Mounted slides were visualized using a fluorescence microscope (Carl Zeiss, ) at 20x, 32x, or 40x magnification.
###end p 48
###begin title 49
###xml 0 5 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
HHV-6 Infection of Primary Astrocytes
###end title 49
###begin p 50
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b028">28</xref>
###xml 307 308 307 308 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 498 499 492 493 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 55 62 <span type="species:ncbi:9606">patient</span>
After 2-3 wk in culture, primary astrocytic cells from patient 20 were infected with HHV-6A and HHV-6B. Infection was performed as described previously [28]. Briefly, cultures were infected with freshly thawed cell-free supernatant from HHV-6A-infected JJahn or HHV-6B-infected SupT-1 cells at a ratio of 103 DNA viral copies/cell (quantified by TaqMan PCR). Mock infections were performed using culture medium from uninfected SupT1 or JJahn. Cultures were incubated for 3 h at 37 degreesC in 5% CO2, cultures were washed three times with PBS, and fresh medium was added. Cells were harvested for experiments 5 d after infection.
###end p 50
###begin title 51
Reverse Transcription-PCR and TaqMan for EAAT-2
###end title 51
###begin p 52
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b036">36</xref>
###xml 644 645 620 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 703 704 673 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
RNA extracted from primary astrocytes was reverse transcribed using reagents from Applied Biosystems () according to manufacturer's instructions. cDNA was amplified using primers specific for EAAT-2 [36]. PCR for EAAT-2 was run for 35 cycles using the following conditions: 95 degreesC for 45 s, 55 degreesC for 1 min, and 72 degreesC for 1 min. cDNA was also amplified using TaqMan primer/probe sequences specific for EAAT-2 and HPRT (synthesized from cDNA sequences by Synthegen, now Integrated DNA Technologies, ). cDNA was amplified in a 96-well reaction plate using the following conditions: 50 degreesC for 2 min for activation of uracil-N-glycosylase, 95 degreesC for 10 min to inactivate uracil-N-glycosylase, and 45 cycles of 95 degreesC for 15 s (denaturation) and 60 degreesC for 1 min (annealing and extension).
###end p 52
###begin title 53
Results
###end title 53
###begin title 54
Quantitative Detection of HHV-6B DNA in Brain Tissue
###end title 54
###begin p 55
###xml 98 106 98 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040180-g001">Figure 1</xref>
###xml 184 185 182 183 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 193 195 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b015">15</xref>
###xml 516 517 514 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 527 535 525 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040180-g001">Figure 1</xref>
###xml 627 628 625 626 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 638 639 636 637 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 658 659 656 657 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 669 670 667 668 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 691 699 689 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040180-g001">Figure 1</xref>
###xml 0 5 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 78 86 <span type="species:ncbi:9606">patients</span>
###xml 122 127 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 294 302 <span type="species:ncbi:9606">patients</span>
###xml 336 344 <span type="species:ncbi:9606">patients</span>
###xml 446 454 <span type="species:ncbi:9606">patients</span>
###xml 479 487 <span type="species:ncbi:9606">patients</span>
###xml 708 716 <span type="species:ncbi:9606">patients</span>
###xml 757 762 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 839 847 <span type="species:ncbi:9606">patients</span>
###xml 883 891 <span type="species:ncbi:9606">patients</span>
HHV-6 type-specific analysis amplified HHV-6B but not HHV-6A from a subset of patients with MTLE (Figure 1). The range of HHV-6 in normal PBMCs has been reported to be </=100 copies/106 cells [15], and no statistical difference was observed in quantitative HHV-6B levels in PBMCs isolated from patients with MTLE compared with those in patients without MTLE. In contrast, HHV-6B DNA levels were significantly higher in resected brain tissue from patients with MTLE compared with patients with epilepsy without MTLE (p < 0.001; Figure 1). Mean HHV-6B DNA levels in MTLE brain tissue (hippocampus and temporal lobe) were 1.5 x 103 copies/106 cells and 3.9 x 102 copies/106 cells respectively (Figure 1), while patients without MTLE had undetectable levels of HHV-6 DNA in brain resections. Notably, three hippocampus specimens resected from patients with MTLE, and four specimens from patients without MTLE were negative for HHV-6B DNA. The negative viral loads assessed by TaqMan were also confirmed by negative nested PCR findings.
###end p 55
###begin title 56
###xml 72 80 <span type="species:ncbi:9606">Patients</span>
Characterization of HHV-6B Active Infection on Cultured Astrocytes from Patients with MTLE
###end title 56
###begin p 57
###xml 346 354 346 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040180-g002">Figure 2</xref>
###xml 360 361 360 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040180-g002">2</xref>
###xml 387 395 387 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040180-g002">Figure 2</xref>
###xml 401 402 401 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040180-g002">2</xref>
###xml 509 517 506 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040180-g002">Figure 2</xref>
###xml 523 524 520 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040180-g002">2</xref>
###xml 587 595 584 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040180-g002">Figure 2</xref>
###xml 81 89 <span type="species:ncbi:9606">patients</span>
###xml 108 116 <span type="species:ncbi:9606">patients</span>
From brain resections where sufficient quantities of tissue were available (five patients with MTLE and two patients without MTLE), primary glial cells were cultured and tested for purity of astrocyte populations by immunofluorescent-staining GFAP. Each culture demonstrated variable astrocyte purity by expression of GFAP (blue-stained cells in Figure 2A and 2B; green-stained cells in Figure 2C and 2D). Primary cultures were negative for the neuronal marker Tuj1 (beta-tubulin III; lack of red staining in Figure 2A and 2B) and for the microglial marker CD68 (lack of red staining in Figure 2D), supporting the characterization of these cells as primary astrocytes. Culture conditions did not support growth of neurons or oligodendrocytes.
###end p 57
###begin p 58
###xml 229 237 229 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040180-g002">Figure 2</xref>
###xml 426 434 426 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040180-g002">Figure 2</xref>
###xml 440 441 440 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040180-g002">2</xref>
###xml 460 468 460 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040180-g002">Figure 2</xref>
###xml 490 498 490 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040180-g002">Figure 2</xref>
###xml 802 811 802 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040180-sg001">Figure S1</xref>
###xml 82 87 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 155 160 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 252 257 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 291 299 <span type="species:ncbi:9606">patients</span>
###xml 323 328 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 605 610 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 715 723 <span type="species:ncbi:9606">patients</span>
###xml 745 750 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 774 779 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 869 874 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 884 892 <span type="species:ncbi:9606">patients</span>
###xml 915 920 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 954 959 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
To determine whether primary astrocytes isolated from MTLE brain tissue contained HHV-6, cells were analyzed for the expression of the nonvariant specific HHV-6 surface glycoprotein gp116/54/64 by immunofluorescence. As shown in Figure 2, detection of HHV-6 gp116 in primary astrocytes from patients with MTLE demonstrated HHV-6 viral protein expression that colocalized with GFAP-positive astrocytic cells (green staining in Figure 2A and 2B; red staining in Figure 2C). The astrocytes in Figure 2 were cultured from the hippocampus/temporal lobe of MTLE brain resections, each of which was positive for HHV-6 by PCR and typed as HHV-6B by TaqMan (unpublished data). Examples of primary astrocytes from additional patients with MTLE expressing HHV-6 antigen and containing HHV-6 viral DNA is shown in Figure S1. By contrast, primary astrocyte cell lines cultured from HHV-6-negative patients without MTLE remained HHV-6 PCR negative and did not express HHV-6 gp116 by immunofluorescence (unpublished data).
###end p 58
###begin title 59
Longitudinal Detection and Characterization of HHV-6B
###end title 59
###begin p 60
###xml 466 474 466 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040180-g003">Figure 3</xref>
###xml 584 585 584 585 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 588 589 588 589 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 597 605 597 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040180-g003">Figure 3</xref>
###xml 873 881 873 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040180-g002">Figure 2</xref>
###xml 1083 1091 1083 1091 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040180-g003">Figure 3</xref>
###xml 1350 1358 1350 1358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040180-g003">Figure 3</xref>
###xml 1587 1588 1587 1588 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1611 1612 1611 1612 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 2454 2457 2454 2457 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U67</italic>
###xml 2462 2466 2462 2466 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U100</italic>
###xml 2569 2577 2569 2577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040180-g003">Figure 3</xref>
###xml 2641 2649 2641 2649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040180-g003">Figure 3</xref>
###xml 2678 2686 2678 2686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040180-g002">Figure 2</xref>
###xml 40 47 <span type="species:ncbi:9606">patient</span>
###xml 166 173 <span type="species:ncbi:9606">patient</span>
###xml 364 369 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 489 494 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 819 824 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 993 998 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 1481 1486 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 1728 1733 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 1863 1871 <span type="species:ncbi:9606">patients</span>
###xml 1883 1888 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 2044 2051 <span type="species:ncbi:9606">patient</span>
###xml 2304 2309 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 2341 2348 <span type="species:ncbi:9606">patient</span>
###xml 2387 2392 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 2412 2417 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 2448 2453 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 2479 2484 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 2656 2661 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
Between February 2004 and January 2005, patient 16 at CNMC had four brain resections for uncontrolled seizures, including a hemispherectomy in January 2005. Although patient 16 was not classified with classic MTLE, early symptoms indicated MTLE that progressed into a more severe syndrome eventually requiring hemispherectomy. In tissue from each brain resection, HHV-6 was detected by PCR (unpublished data) and was quantified and subtyped as HHV-6B by TaqMan PCR (Figure 3). The highest HHV-6 viral load was detected in the hippocampus following the first brain resection (2.53 x 103/106 cells; Figure 3). Sufficient quantity of brain material was obtained following hemispherectomy in January 2005 for isolation and culture of primary cells. Astrocyte cultures isolated from frontal/parietal and temporal lobes were HHV-6 gp116/54/64 positive and colocalized with GFAP (Figure 2A), indicating the presence of viral antigen in astrocytes in vitro. In addition, these cells were positive for HHV-6 DNA by PCR (unpublished data), and viral DNA was quantified and subtyped as HHV-6B (Figure 3). Notably, TaqMan HHV-6B viral DNA levels in these primary astrocyte cultures were higher than those quantified from DNA isolated from the corresponding regions of fresh brain, indicating the possibility of further viral reactivation during primary culture (Figure 3). DNA extracted from freshly resected temporal and frontal/parietal lobes following hemispherectomy was also positive for HHV-6 by PCR (unpublished data), and was quantified and typed as HHV-6B with viral loads of 1.77 copies/106 cells and 93 copies/106 cells, respectively. In contrast, DNA extracted from freshly resected frontal and occipital lobes was negative for HHV-6 by both PCR and TaqMan (unpublished data), indicating that viral infection was localized and not spread throughout the brain. In patients with MTLE, HHV-6 infection was localized primarily to the temporal lobe, with highest viral load detected in the hippocampus. Similarly, the first hippocampal resection of patient 16 demonstrated the highest viral load detected. Detection of HHV-6B DNA in the frontal/parietal lobe following hemispherectomy supports the finding that the syndrome progressed from early MTLE to a chronic encephalitis, and may have lead to spread of HHV-6 infection in the brain of this patient. Finally, we determined expression of HHV-6 RNA using a set of HHV-6-specific primers specific for HHV-6 U67 and U100 late genes. HHV-6 RNA was demonstrated in primary astrocytes isolated from the frontal/parietal lobe (Figure 3B), consistent with the detection of high levels of HHV-6B DNA (Figure 3A) and HHV-6 antigen by IFA (Figure 2A).
###end p 60
###begin title 61
Association of Active HHV-6B Infection and Impaired EAAT-2 mRNA Transcription in Cultured Astrocytes
###end title 61
###begin p 62
###xml 423 431 423 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040180-g004">Figure 4</xref>
###xml 1028 1036 1028 1036 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040180-g004">Figure 4</xref>
###xml 1334 1342 1334 1342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040180-g004">Figure 4</xref>
###xml 1437 1438 1437 1438 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sup>
###xml 1448 1449 1448 1449 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1469 1470 1469 1470 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1480 1481 1480 1481 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 146 153 <span type="species:ncbi:9606">patient</span>
###xml 509 516 <span type="species:ncbi:9606">patient</span>
###xml 560 567 <span type="species:ncbi:9606">patient</span>
###xml 621 628 <span type="species:ncbi:9606">patient</span>
###xml 796 801 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 898 905 <span type="species:ncbi:9606">patient</span>
###xml 1166 1173 <span type="species:ncbi:9606">patient</span>
###xml 1240 1247 <span type="species:ncbi:9606">patient</span>
###xml 1412 1419 <span type="species:ncbi:9606">patient</span>
We measured transcription of the astrocytic glutamate transporter EAAT-2 mRNA in four brain regions and cultured primary astrocytes isolated from patient 16 by reverse transcription PCR (RT-PCR). All four brain regions expressed mRNA for EAAT-2, while primary astrocytes isolated from the frontal/parietal lobe expressed low levels of EAAT-2 and mRNA was undetectable in primary astrocytes isolated from the temporal lobe (Figure 4A). We compared mRNA expression of EAAT-2 in primary astrocytes isolated from patient 16 with primary astrocytes isolated from a patient who was HHV-6B DNA negative. Primary astrocytes from patient 20 (HHV-6B DNA negative) were also infected in vitro with HHV-6A and HHV-6B to compare EAAT-2 expression in astrocytes infected in vitro with astrocytes cultured from HHV-6-positive brain tissue. While EAAT-2 mRNA was expressed in mock-infected primary astrocytes from patient 20, EAAT-2 expression was dramatically reduced in primary astrocytes infected with either HHV-6A (U1102) or HHV-6B (Z29) (Figure 4A). These observations were confirmed by TaqMan, showing low levels of EAAT-2 expression in both primary astrocytes isolated from patient 16 and in the HHV-6A- and HHV-6B-infected primary astrocytes from patient 20 compared with the expression levels of EAAT-2 in mock-infected primary astrocytes (Figure 4B). Viral load in HHV-6A- and HHV-6B-infected primary astrocytes from patient 20 were 1.19 x 108 copies/106 cells and 1.68 x 106 copies/106 cells, respectively.
###end p 62
###begin title 63
Discussion
###end title 63
###begin p 64
###xml 60 68 <span type="species:ncbi:9606">patients</span>
###xml 115 123 <span type="species:ncbi:9606">patients</span>
###xml 253 258 <span type="species:ncbi:9606">human</span>
###xml 346 351 <span type="species:ncbi:9606">human</span>
###xml 379 387 <span type="species:ncbi:9606">patients</span>
###xml 457 462 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 574 579 <span type="species:ncbi:9606">human</span>
###xml 653 661 <span type="species:ncbi:9606">patients</span>
###xml 783 791 <span type="species:ncbi:9606">patients</span>
###xml 805 813 <span type="species:ncbi:9606">patients</span>
###xml 965 973 <span type="species:ncbi:9606">patients</span>
This study demonstrates persistent HHV-6B infection in most patients with MTS-MTLE, but no detectable infection in patients with other pathology and constitutes the first report of primary isolation and maintenance of virus-infected astrocytes from the human brain. In addition, we provide direct evidence for an etiological link of a ubiquitous human herpesvirus in a subset of patients with intractable MTLE with MTS, a syndrome of unknown origin. Active HHV-6 infection was confirmed by the detection of viral DNA, mRNA viral transcripts, and viral protein expression in human primary astrocytes isolated and cultured from resected brain tissue from patients with MTLE. HHV-6B in MTS-MTLE is unlikely to be a consequence of nonspecific inflammation or seizures, since none of the patients without MTLE patients, all of whom had intractable epilepsy, were positive for virus. Moreover, there was no evidence for inflammatory changes in any of the HHV-6B-positive patients.
###end p 64
###begin p 65
###xml 262 264 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b037">37</xref>
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b038">38</xref>
###xml 729 731 729 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b015">15</xref>
###xml 732 734 732 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b037">37</xref>
###xml 735 737 735 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b040">40</xref>
###xml 1212 1214 1212 1214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b041">41</xref>
###xml 1625 1627 1625 1627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b015">15</xref>
###xml 1628 1630 1628 1630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b042">42</xref>
###xml 1631 1633 1631 1633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b044">44</xref>
###xml 20 25 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 173 178 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 197 202 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 279 284 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 627 632 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 670 675 <span type="species:ncbi:9606">human</span>
###xml 791 798 <span type="species:ncbi:9606">patient</span>
###xml 905 910 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 929 934 <span type="species:ncbi:9606">human</span>
###xml 1070 1075 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 1149 1154 <span type="species:ncbi:9606">human</span>
###xml 1435 1440 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 1466 1474 <span type="species:ncbi:9606">patients</span>
###xml 1682 1687 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 1802 1810 <span type="species:ncbi:9606">patients</span>
Studies associating HHV-6 with neurologic disorders, including epilepsy, are based on detection of viral DNA, RNA, and antigen, suggesting pathogenic reactivation of latent HHV-6. Establishment of HHV-6 latency in the CNS can follow primary childhood infection [37,38]. Although HHV-6 reactivation in the brain appears to occur predominately in immunosuppressed adults and is associated with neurological complications following bone marrow and stem cell transplantation, viral reactivation may also play a role in disorders such as multiple sclerosis and epilepsy. Several studies have demonstrated the presence of low levels HHV-6 DNA (typically nested PCR) in normal human brains that can range between a frequency of 0%-75% [15,37-40]. These discrepancies can be attributed to different patient populations, methods of detection, and sensitivities and specificities of reagents. Studies demonstrating HHV-6 DNA in the normal human brain have typically used nested PCR, indicating that levels of viral DNA are low, supporting the observations by Blumberg et al. that HHV-6 may be present as a latent commensal pathogen that is able to infect the human brain without causing any apparent neurological disease [41]. The result in this study demonstrating high levels of viral DNA detected in MTLE specimens by non-nested TaqMan PCR, together with the presence of viral antigen and RNA, suggests association with disease. Detection of HHV-6 DNA by PCR in 25%-50% of patients with temporal lobe epilepsy indicates an association of viral reactivation with a neurological disorder that may be independent of immunosuppression [15,42-44]. The results in this study demonstrated higher HHV-6 levels in hippocampal tissue than in the surrounding temporal neocortex. High viral loads in the hippocampus from patients with MTLE could reflect viral reactivation in a specific brain region associated with latency resulting from early childhood infection.
###end p 65
###begin p 66
###xml 235 237 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b045">45</xref>
###xml 238 240 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b046">46</xref>
###xml 407 409 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b024">24</xref>
###xml 410 412 410 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b047">47</xref>
###xml 413 415 413 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b048">48</xref>
###xml 625 632 625 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040180-t002">Table 2</xref>
###xml 1542 1544 1542 1544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b025">25</xref>
###xml 1545 1547 1545 1547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b032">32</xref>
###xml 551 559 <span type="species:ncbi:9606">patients</span>
###xml 648 656 <span type="species:ncbi:9606">patients</span>
###xml 885 892 <span type="species:ncbi:9606">patient</span>
###xml 952 960 <span type="species:ncbi:9606">patients</span>
###xml 1123 1131 <span type="species:ncbi:9606">patients</span>
###xml 1149 1154 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 1245 1253 <span type="species:ncbi:9606">patients</span>
Alternatively, persistent noninflammatory encephalitis may also lead to the development of epilepsy. Several lines of evidence, including clinical, imaging, and neuropsychological data, suggest that MTS/MTLE is a progressive disorder [45,46]. Imaging studies have shown that febrile seizure history and epilepsy duration are associated with increasing hippocampal atrophy, independent of seizure frequency [24,47,48]. A history of febrile seizures may be difficult to establish retrospectively, many years after the event. In our overall cohort of 38 patients, which represents our collective experience at NIH and the CNMC (Table 2), five of nine patients with a definite history of febrile seizures (all in the MTS-MTLE group), compared with nine of 28 reporting no history of febrile seizures, were positive for HHV-6B (a clear history could not be obtained for one HHV-6B-positive patient with MTS-MTLE), suggesting a trend towards HHV-6B-positive patients with MTLE having febrile seizure history. The long latency between childhood febrile seizures and the appearance of persistent unprovoked seizures suggests these patients may have chronic HHV-6 infection rather than reactivated virus. The presence of chronic viral infection in these patients would be supported by the progression of hippocampal atrophy. Collectively, these data suggest an ongoing process; the latency between occurrence of an early risk factor such as febrile seizures and onset of chronic epilepsy is consistent with either persistent or reactivated infection [25,32].
###end p 66
###begin p 67
###xml 62 69 <span type="species:ncbi:9606">patient</span>
###xml 344 351 <span type="species:ncbi:9606">patient</span>
###xml 439 446 <span type="species:ncbi:9606">patient</span>
###xml 607 612 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 709 716 <span type="species:ncbi:9606">patient</span>
We also had the unique opportunity to follow longitudinally a patient who experienced recurrent seizures after three focal resections and a hemispherectomy for a period of 11 mo. Consistent detection of high levels of HHV-6B DNA in each of the three resections and in frontal and temporal/parietal lobes following hemispherectomy suggests this patient had a persistent and widespread infection with HHV-6B. Following hemispherectomy, this patient has been seizure-free without anticonvulsant treatment for more than 1 y. It is intriguing to speculate that these data demonstrate a widespread and persistent HHV-6 infection that was associated with epilepsy, and that once the viral infection was removed, the patient became seizure-free.
###end p 67
###begin p 68
###xml 345 347 345 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b049">49</xref>
###xml 508 510 508 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b050">50</xref>
###xml 680 682 680 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b051">51</xref>
###xml 797 799 797 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b050">50</xref>
###xml 1004 1006 1004 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b052">52</xref>
###xml 1060 1062 1060 1062 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040180-b053">53</xref>
###xml 70 75 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 1149 1157 <span type="species:ncbi:9606">patients</span>
###xml 1190 1195 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 1211 1216 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 1338 1343 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 1437 1442 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 1482 1487 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 1621 1626 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 1911 1916 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
An association between chronic epilepsy and persistent or reactivated HHV-6 infection of astrocytes suggests the possibility that viral infection of astrocytes are associated with changes in cell function that may contribute to disease. Astrocytes are known to interact closely with neurons and are critical in modulating synaptic transmission [49]. Astrocytes can modulate neurotransmission by maintaining low concentrations of extracellular glutamate by the glial glutamate transporters EAAT-1 and EAAT-2 [50]. Elevated extracellular glutamate, the main excitatory neurotransmitter, may be involved in epilepsy by triggering excitotoxicity through loss of glutamine synthetase [51], an enzyme that metabolizes glutamate in astrocytes, and/or by malfunctioning astrocytic glutamate transporters [50]. The CA1 and CA3 neurons lost in MTS/MTLE are particularly susceptible to glutamatergic-mediated cell death. Sclerotic hippocampi from temporal lobe epilepsy demonstrate reduced EAAT-2 immunoreactivity [52], and are prone to alternative EAAT-2 mRNA splicing [53]. A unique finding in this study is the isolation ex vivo of cultured astrocytes from patients with MTLE who are infected with HHV-6. These primary HHV-6-infected astrocytes demonstrated low levels of EAAT-2 mRNA. In support of our ex vivo findings, astrocytes infected with HHV-6 in vitro also demonstrated a remarkable decrease in EAAT-2 mRNA. Detection of high levels of HHV-6 DNA in MTLE brain tissue, isolation of HHV-6 from primary astrocytes isolated from MTLE brain tissue, and decreased expression of EAAT-2 mRNA demonstrates an association between HHV-6 infection and astrocytic dysfunction. Functional changes in virus infected glia or in glia harboring reactivated virus may lead to secondary injury of the exquisitely sensitive hippocampal neuron, and ultimately to development of MTLE and epilepsy. The potential relationship between HHV-6 astrocytic infection and MTLE deserves further investigation.
###end p 68
###begin p 69
###xml 499 506 499 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040180-t002">Table 2</xref>
###xml 105 113 <span type="species:ncbi:9606">patients</span>
###xml 247 252 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 403 408 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 483 488 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 529 537 <span type="species:ncbi:9606">patients</span>
###xml 609 614 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
Overall, our cumulative experience at the NIH Clinical Center and the CNMC consists of a large cohort of patients with epilepsy, from which 60% with clinically defined MTLE had detectable HHV-6B sequences in surgical brain resections. The highest HHV-6 viral loads were demonstrated in the hippocampus. This appeared to be specific for MTLE, since non-MTLE epilepsy material had no detectable levels of HHV-6 DNA by TaqMan or nested PCR. The statistically significant correlation of HHV-6 and MTLE (Table 2) in a large cohort of patients with epilepsy and dysregulation of glutamate transporter expression by HHV-6 suggests a novel pathophysiological mechanism of disease.
###end p 69
###begin title 70
Supporting Information
###end title 70
###begin title 71
Primary Astrocytes Isolated and Cultured from HHV-6B-Positive MTLE Brain Resections Express Viral DNA and Antigen
###end title 71
###begin p 72
Primary astrocytes were isolated from fresh brain material obtained during epilepsy brain resection.
###end p 72
###begin p 73
###xml 114 119 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 257 265 <span type="species:ncbi:9606">patients</span>
(A) Cells were cultured for 3-4 wk and stained for GFAP (green), DAPI (blue; nuclei), and the nonvariant specific HHV-6 antigen gp116/54/64 (red). Representative immunofluorescence images show primary astrocyte cultures from four epilepsy brain resections (patients 14, 15, 5, and 6). All images were acquired with a 20x objective.
###end p 73
###begin p 74
###xml 42 50 <span type="species:ncbi:9606">patients</span>
###xml 92 97 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
(B) Cells were scraped from fixed slides (patients 5 and 6), DNA was extracted, and DNA for HHV-6 U57 (major capsid protein) was detected by nested PCR. Negative and positive controls used were uninfected SupT1 T cells and HHV-6B (strain Z29)-infected SupT1 T cells, respectively.
###end p 74
###begin p 75
(36 KB JPG)
###end p 75
###begin p 76
Click here for additional data file.
###end p 76
###begin title 77
Accession Numbers
###end title 77
###begin p 78
The GenBank () accession numbers for the viruses and transporter discussed in this paper are HHV-6A (NC_001664), HHV-6B (NC_000898), and EAAT-2 (NM_004171).
###end p 78
###begin p 79
The authors gratefully acknowledge Dr. Robert Bonwetsch for assistance in processing samples and immunofluorescence. Julie Fotheringham was supported by a postdoctoral fellowship from the Multiple Sclerosis Society of Canada.
###end p 79
###begin title 80
Abbreviations
###end title 80
###begin p 81
central nervous system
###end p 81
###begin p 82
glial fibrillary acidic protein
###end p 82
###begin p 83
###xml 0 5 <span type="species:ncbi:9606">human</span>
human herpesvirus-6
###end p 83
###begin p 84
mesial temporal lobe epilepsy
###end p 84
###begin p 85
mesial temporal sclerosis
###end p 85
###begin p 86
peripheral blood mononuclear cells
###end p 86
###begin p 87
reverse transcription PCR
###end p 87
###begin title 88
References
###end title 88
###begin article-title 89
###xml 35 43 <span type="species:ncbi:9606">patients</span>
Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders
###end article-title 89
###begin article-title 90
###xml 20 39 <span type="species:ncbi:10368">human herpesvirus 6</span>
###xml 60 68 <span type="species:ncbi:9606">children</span>
Seroepidemiology of human herpesvirus 6 infection in normal children and adults
###end article-title 90
###begin article-title 91
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human herpesvirus-6: Neurologic implications of a newly-described viral pathogen
###end article-title 91
###begin article-title 92
###xml 0 19 <span type="species:ncbi:10368">Human herpesvirus 6</span>
Human herpesvirus 6: An emerging pathogen
###end article-title 92
###begin article-title 93
###xml 25 30 <span type="species:ncbi:9606">human</span>
###xml 62 70 <span type="species:ncbi:9606">children</span>
Cellular localization of human herpesvirus-6 in the brains of children with AIDS encephalopathy
###end article-title 93
###begin article-title 94
###xml 33 52 <span type="species:ncbi:10368">human herpesvirus 6</span>
###xml 56 64 <span type="species:ncbi:9606">children</span>
Neuroinvasion and persistence of human herpesvirus 6 in children
###end article-title 94
###begin article-title 95
###xml 23 28 <span type="species:ncbi:9606">human</span>
Encephalitis caused by human herpesvirus-6 in transplant recipients: Relevance of a novel neurotropic virus
###end article-title 95
###begin article-title 96
###xml 10 29 <span type="species:ncbi:10368">human herpesvirus 6</span>
Update on human herpesvirus 6 biology, clinical features, and therapy
###end article-title 96
###begin article-title 97
###xml 52 57 <span type="species:ncbi:9606">human</span>
###xml 113 121 <span type="species:ncbi:9606">patients</span>
Tissue distribution and variant characterization of human herpesvirus (HHV)-6: Increased prevalence of HHV-6A in patients with multiple sclerosis
###end article-title 97
###begin article-title 98
###xml 15 34 <span type="species:ncbi:10368">human herpesvirus 6</span>
Persistence of human herpesvirus 6 according to site and variant: Possible greater neurotropism of variant A
###end article-title 98
###begin article-title 99
###xml 0 19 <span type="species:ncbi:10368">Human herpesvirus 6</span>
###xml 21 26 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 87 92 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 128 135 <span type="species:ncbi:9606">infants</span>
Human herpesvirus 6 (HHV-6) variant B accounts for the majority of symptomatic primary HHV-6 infections in a population of U.S. infants
###end article-title 99
###begin article-title 100
###xml 0 19 <span type="species:ncbi:10368">Human herpesvirus 6</span>
Human herpesvirus 6 is associated with focal encephalitis
###end article-title 100
###begin article-title 101
###xml 0 19 <span type="species:ncbi:10368">Human herpesvirus 6</span>
Human herpesvirus 6 limbic encephalitis after stem cell transplantation
###end article-title 101
###begin article-title 102
###xml 32 51 <span type="species:ncbi:10368">human herpesvirus 6</span>
Plaque-associated expression of human herpesvirus 6 in multiple sclerosis
###end article-title 102
###begin article-title 103
###xml 13 18 <span type="species:ncbi:9606">human</span>
Detection of human herpesvirus-6 in mesial temporal lobe epilepsy surgical brain resections
###end article-title 103
###begin article-title 104
###xml 15 20 <span type="species:ncbi:9606">human</span>
###xml 37 42 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 95 100 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 138 143 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
Association of human herpes virus 6 (HHV-6) with multiple sclerosis: Increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA
###end article-title 104
###begin article-title 105
###xml 15 34 <span type="species:ncbi:10368">human herpesvirus 6</span>
Association of human herpesvirus 6 with the demyelinative lesions of progressive multifocal leukoencephalopathy
###end article-title 105
###begin article-title 106
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 33 41 <span type="species:ncbi:9606">children</span>
Human herpesvirus-6 infection in children. A prospective study of complications and reactivation
###end article-title 106
###begin article-title 107
###xml 40 45 <span type="species:ncbi:9606">human</span>
Central nervous system complications in human herpesvirus-6 infection
###end article-title 107
###begin article-title 108
###xml 21 28 <span type="species:ncbi:9606">infants</span>
###xml 42 61 <span type="species:ncbi:10368">human herpesvirus 6</span>
Clinical features of infants with primary human herpesvirus 6 infection (exanthem subitum, roseola infantum)
###end article-title 108
###begin article-title 109
The cost of epilepsy in the United States: An estimate from population-based clinical and survey data
###end article-title 109
###begin article-title 110
Factors prognostic of unprovoked seizures after febrile convulsions
###end article-title 110
###begin article-title 111
###xml 23 31 <span type="species:ncbi:9606">children</span>
Unprovoked seizures in children with febrile seizures: Short-term outcome
###end article-title 111
###begin article-title 112
###xml 64 72 <span type="species:ncbi:9606">patients</span>
Hippocampal atrophy, epilepsy duration, and febrile seizures in patients with partial seizures
###end article-title 112
###begin article-title 113
Magnetic resonance imaging evidence of hippocampal injury after prolonged focal febrile convulsions
###end article-title 113
###begin article-title 114
A randomized, controlled trial of surgery for temporal-lobe epilepsy
###end article-title 114
###begin article-title 115
###xml 0 19 <span type="species:ncbi:10368">Human herpesvirus 6</span>
Human herpesvirus 6 genome and antigen in acute multiple sclerosis lesions
###end article-title 115
###begin article-title 116
###xml 28 47 <span type="species:ncbi:10368">human herpesvirus 6</span>
###xml 51 56 <span type="species:ncbi:9606">human</span>
Variant-specific tropism of human herpesvirus 6 in human astrocytes
###end article-title 116
###begin article-title 117
###xml 14 19 <span type="species:ncbi:9606">human</span>
###xml 35 40 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 54 59 <span type="species:ncbi:9606">human</span>
The effect of human herpesvirus-6 (HHV-6) on cultured human neural cells: oligodendrocytes and microglia
###end article-title 117
###begin article-title 118
###xml 21 26 <span type="species:ncbi:9606">human</span>
###xml 47 66 <span type="species:ncbi:10368">human herpesvirus 6</span>
Infection of primary human fetal astrocytes by human herpesvirus 6
###end article-title 118
###begin article-title 119
###xml 29 34 <span type="species:ncbi:9606">human</span>
###xml 57 62 <span type="species:ncbi:9606">human</span>
In vitro cellular tropism of human B-lymphotropic virus (human herpesvirus-6)
###end article-title 119
###begin article-title 120
Characteristics of medial temporal lobe epilepsy: I. Results of history and physical examination
###end article-title 120
###begin article-title 121
Characteristics of medial temporal lobe epilepsy: II. Interictal and ictal scalp electroencephalography, neuropsychological testing, neuroimaging, surgical results, and pathology
###end article-title 121
###begin article-title 122
###xml 13 32 <span type="species:ncbi:10368">human herpesvirus 6</span>
###xml 46 54 <span type="species:ncbi:9606">children</span>
###xml 99 107 <span type="species:ncbi:9606">patients</span>
Detection of human herpesvirus 6 in plasma of children with primary infection and immunosuppressed patients by polymerase chain reaction
###end article-title 122
###begin article-title 123
###xml 0 20 <span type="species:ncbi:32603">Human herpesvirus 6A</span>
###xml 103 111 <span type="species:ncbi:9606">patients</span>
Human herpesvirus 6A DNA is detected frequently in plasma but rarely in peripheral blood leukocytes of patients after bone marrow transplantation
###end article-title 123
###begin article-title 124
###xml 90 95 <span type="species:ncbi:9606">human</span>
Impaired glutamate uptake and EAAT2 downregulation in an enterovirus chronically infected human glial cell line
###end article-title 124
###begin article-title 125
###xml 0 19 <span type="species:ncbi:10368">Human herpesvirus 6</span>
Human herpesvirus 6 infection in neoplastic and normal brain tissue
###end article-title 125
###begin article-title 126
###xml 31 50 <span type="species:ncbi:10368">human herpesvirus 6</span>
###xml 77 82 <span type="species:ncbi:9606">human</span>
Prevalence and distribution of human herpesvirus 6 variants A and B in adult human brain
###end article-title 126
###begin article-title 127
###xml 15 20 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
Early and late HHV-6 gene transcripts in multiple sclerosis lesions and normal appearing white matter
###end article-title 127
###begin article-title 128
###xml 18 37 <span type="species:ncbi:10368">human herpesvirus 6</span>
High frequency of human herpesvirus 6 DNA in multiple sclerosis plaques isolated by laser microdissection
###end article-title 128
###begin article-title 129
###xml 4 8 <span type="species:ncbi:10368">HHV6</span>
The HHV6 paradox: Ubiquitous commensal or insidious pathogen? A two-step in situ PCR approach
###end article-title 129
###begin article-title 130
Epilepsy etiology with special emphasis on immune dysfunction and neurovirology
###end article-title 130
###begin article-title 131
###xml 12 31 <span type="species:ncbi:10368">human herpesvirus 6</span>
###xml 143 151 <span type="species:ncbi:9606">patients</span>
Presence of human herpesvirus 6 and herpes simplex virus detected by polymerase chain reaction in surgical tissue from temporal lobe epileptic patients
###end article-title 131
###begin article-title 132
###xml 37 45 <span type="species:ncbi:9606">patients</span>
Herpesviral DNA in brain tissue from patients with temporal lobe epilepsy
###end article-title 132
###begin article-title 133
Progression in mesial temporal lobe epilepsy
###end article-title 133
###begin article-title 134
Neuroimaging and the progression of epilepsy
###end article-title 134
###begin article-title 135
Recurrent seizures may cause hippocampal damage in temporal lobe epilepsy
###end article-title 135
###begin article-title 136
Neuroimaging evidence of progressive neuronal loss and dysfunction in temporal lobe epilepsy
###end article-title 136
###begin article-title 137
Astrocyte-induced modulation of synaptic transmission
###end article-title 137
###begin article-title 138
Glutamate uptake
###end article-title 138
###begin article-title 139
###xml 36 41 <span type="species:ncbi:9606">human</span>
Loss of glutamine synthetase in the human epileptogenic hippocampus: Possible mechanism for raised extracellular glutamate in mesial temporal lobe epilepsy
###end article-title 139
###begin article-title 140
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Distribution of glutamate transporters in the hippocampus of patients with pharmaco-resistant temporal lobe epilepsy
###end article-title 140
###begin article-title 141
###xml 45 53 <span type="species:ncbi:9606">patients</span>
Synaptosomal glutamate and GABA transport in patients with temporal lobe epilepsy
###end article-title 141
###begin title 142
Figures and Tables
###end title 142
###begin title 143
###xml 15 20 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 63 71 <span type="species:ncbi:9606">Patients</span>
High Levels of HHV-6 DNA Are Detected in Brain Resections from Patients with MTLE
###end title 143
###begin p 144
###xml 196 197 196 197 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 315 323 <span type="species:ncbi:9606">patients</span>
HHV-6B DNA was quantitated in PBMCs, serum, and fresh brain (hipp, hippocampus; LTL, lateral temporal lobe) from epilepsy brain resections by TaqMan PCR. Viral load was normalized as DNA copies/106 cells (brain and PBMCs) or DNA copies/ml (serum). Data from brain, serum, and PBMCs are represented graphically from patients with and without MTLE. Means are shown by black bars.
###end p 144
###begin title 145
Primary Astrocytes Isolated and Cultured from HHV-6B-Positive MTLE Brain Resections Express Viral Antigen
###end title 145
###begin p 146
###xml 174 179 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
Primary astrocytes were isolated from fresh brain material obtained during epilepsy brain resection. Cells were cultured for 3-4 wk and costained for the nonvariant specific HHV-6 gp116 surface glycoprotein and GFAP as a marker for astrocytes (A-C), the neuronal marker Tuj1 (A-B), or the microglial marker CD68 (D).
###end p 146
###begin p 147
###xml 13 20 <span type="species:ncbi:9606">patient</span>
###xml 38 43 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
(A) Epilepsy patient 2a: GFAP = blue; HHV-6 = green; Tuj1 = red, 20x.
###end p 147
###begin p 148
###xml 13 20 <span type="species:ncbi:9606">patient</span>
###xml 38 43 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
(B) Epilepsy patient 2a: GFAP = blue; HHV-6 = green; Tuj1 = red, 32x.
###end p 148
###begin p 149
###xml 13 20 <span type="species:ncbi:9606">patient</span>
###xml 39 44 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
(C) Epilepsy patient 15; GFAP = green, HHV-6 = red; DAPI = blue, 40x.
###end p 149
###begin p 150
###xml 13 20 <span type="species:ncbi:9606">patient</span>
(D) Epilepsy patient 15; GFAP = green; CD68 = red; DAPI = blue, 40x.
###end p 150
###begin title 151
###xml 33 38 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 56 63 <span type="species:ncbi:9606">Patient</span>
Longitudinal Characterization of HHV-6 Infection in One Patient with Multiple Brain Resections Followed by Hemispherectomy
###end title 151
###begin p 152
###xml 522 523 522 523 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
(A) HHV-6B viral load was quantitated from fresh tissue obtained from three consecutive brain resections (13 February 2004, 18 March 2004, and 15 June 2004) followed by hemispherectomy (19 January 2005) using variant-specific TaqMan PCR. Primary astrocytes were cultured from tissue obtained at hemispherectomy from frontal/parietal and temporal lobes. HHV-6B viral load was quantitated by Taqman in these astrocyte cultures (1 March 2005) approximately 6 wk after surgery. All viral loads are represented as DNA copies/106 cells.
###end p 152
###begin p 153
###xml 77 82 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 204 211 <span type="species:ncbi:9606">patient</span>
###xml 257 264 <span type="species:ncbi:9606">patient</span>
###xml 342 349 <span type="species:ncbi:9606">patient</span>
###xml 384 391 <span type="species:ncbi:9606">patient</span>
###xml 418 425 <span type="species:ncbi:9606">patient</span>
###xml 453 460 <span type="species:ncbi:9606">patient</span>
(B) Expression of viral RNA was determined by RT-PCR using primers for three HHV-6 genes (from top to bottom: U86, immediate early [primers specific for variants A and B], U67, late; U100, late). Lane 1, patient 16 frontal/parietal lobe astrocytes; lane 2, patient 16 temporal lobe astrocytes; lane 3, negative control temporal lobe; lane 4, patient 16 frontal/parietal lobe; lane 5, patient 16 temporal lobe; lane 6, patient 16 occipital lobe; lane 7, patient 16 frontal lobe; lane 8, uninfected JJahn (negative control); lane 9, U1102-infected JJahn (positive control).
###end p 153
###begin title 154
###xml 60 65 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
Decreased Expression of the Glutamate Transporter EAAT-2 in HHV-6-Infected Astrocytes
###end title 154
###begin p 155
###xml 59 66 <span type="species:ncbi:9606">patient</span>
###xml 99 106 <span type="species:ncbi:9606">patient</span>
###xml 143 150 <span type="species:ncbi:9606">patient</span>
###xml 173 178 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 220 228 <span type="species:ncbi:9606">patients</span>
###xml 424 431 <span type="species:ncbi:9606">patient</span>
###xml 466 473 <span type="species:ncbi:9606">patient</span>
###xml 500 507 <span type="species:ncbi:9606">patient</span>
###xml 535 542 <span type="species:ncbi:9606">patient</span>
###xml 568 575 <span type="species:ncbi:9606">patient</span>
###xml 621 628 <span type="species:ncbi:9606">patient</span>
###xml 702 709 <span type="species:ncbi:9606">patient</span>
###xml 778 785 <span type="species:ncbi:9606">patient</span>
###xml 852 859 <span type="species:ncbi:9606">patient</span>
(A) EAAT-2 mRNA was detected by RT-PCR in fresh brain from patient 16, in astrocytes cultured from patient 15, and in astrocytes cultured from patient 20, and infected with HHV-6 in vitro. Samples from the two different patients were run in two separate PCR reactions (on different days) using the same set of EAAT-2 primers but different actin primers. The products of these PCR reactions were run on the same gel. Lane 1, patient 16 frontal/parietal lobe; lane 2, patient 16 temporal lobe; lane 3, patient 16 occipital lobe; lane 4, patient 16 frontal lobe; lane 5, patient 16 frontal/parietal lobe astrocytes; lane 6, patient 16 temporal lobe astrocytes; lane 7, uninfected astrocytes cultured from patient 20; lane 8, HHV-6A (strain U1102)-infected astrocytes cultured from patient 20; lane 9, HHV-6B (strain Z29)-infected astrocytes cultured from patient 20; lane 10, negative control (JJhan T cells); lane 11, positive control (U251 astrocytes).
###end p 155
###begin p 156
###xml 169 176 <span type="species:ncbi:9606">patient</span>
###xml 197 204 <span type="species:ncbi:9606">patient</span>
(B) EAAT-2 mRNA was detected by quantitative TaqMan and normalized to expression of HPRT from astrocytes cultured from frontal/parietal (F/P) and temporal (TL) lobes of patient 16. Astrocytes from patient 20 were mock-infected or were infected with HHV-6A (strain U1102) or HHV-6B (strain Z29).
###end p 156
###begin p 157
###xml 44 51 <span type="species:ncbi:9606">Patient</span>
Clinical Information from NIH/CNMC Epilepsy Patient Cohort
###end p 157
###begin p 158
###xml 0 5 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
HHV-6 DNA Detection in Temporal Lobe Resections from NIH/CNMC epilepsy cohort (n=38)
###end p 158
###begin p 159
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
###xml 165 173 <span type="species:ncbi:9606">patients</span>
###xml 697 705 <span type="species:ncbi:9606">patients</span>
###xml 786 794 <span type="species:ncbi:9606">children</span>
Author contributions. DD, AFH, JDH, WDG, WHT, and SJ designed the study. JF, DD, NA, AFH, AV, WHT, and SJ analyzed the data. JDH, SW, DAB, WDG, SS, and WHT enrolled patients. JF, DD, NA, AFH, AV, JDH, EW, WDG, WHT, and SJ contributed to writing the paper. DD, JF, NA, and AFH performed the experiments (sample processing, DNA extraction, astrocyte isolation, IFA staining). AV performed procurement and histologic evaluation of resected tissues. JDH is the Principal Investigator for the clinical protocol, Research Study of Specimens Obtained During Epilepsy Surgery, 02-N-0014, and was involved in the design of the experiments, the acquisition of surgical tissue specimens, and the care of the patients who donated the research specimens. DAB was the neurourgeon who operated on the children who underwent seizure surgery. SS participated in the selection of surgical candidates and of surgical plans, performed intraoperative electrocorticography and extraopertive invasive (subdural) recording in order to determine the location of seizure foci, and interpreted these results and discussed and determined actual resection plans with a neurosurgeon. WHT was responsible for clinical evaluation and neuroimaging. SJ participated in study design and data analysis.
###end p 159
###begin p 160
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding:</bold>
Funding: Funding for this study was provided by the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 160
###begin p 161
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests:</bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 161

